The Board has recommends final dividend or Rs. 3.5 per equity shares for the FY 2024-25, subject to approval of members
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 6.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mercury Laboratories' Board, at its May 14, 2025 meeting, approved audited FY25 results and recommended a final dividend of Rs. 3.50 per share (35%), subject to shareholder approval at the 44th AGM on August 13, 2025. FY25 revenue from operations stood at Rs. 7,510.12 lakhs (slightly lower than Rs. 7,555.90 lakhs in FY24), while net profit dropped sharply to Rs. 314.49 lakhs from Rs. 565.42 lakhs in FY24, with EPS at Rs. 26.21 vs Rs. 47.12 previously. The Board also appointed Mr. Sanjay Patel as Independent Director and Chairman, and approved the re-appointment of Mr. Rajendra Shah as Managing Director for 3 years from April 1, 2026. Book closure for the dividend is set from August 7 to August 13, 2025, with payment on or before September 11, 2025.
The flat Rs. 3.50 dividend is unchanged from the prior year, offering income stability despite a significant ~44% drop in annual profits. Shareholders will see modest returns; the earnings decline may weigh on the stock in the short term, though the maintained payout signals management's commitment to returning cash.